Abstract
Aztreonam (AZT), a new monobactam antibiotic, was basically and clinically applied to the field of obstetrics and gynecology, obtaining the following results.
1. The pelvic dead space exudate level of AZT after 30 minutes-intravenous drip infusion of 1g attained the peak of 22. 66ug/ml at 1 hour from initiation of infusion and thereafter declined gradually, contrasting the peak of 34. 38ug/ml of the cubital vein at 30 minutes.
2. Total of 13 cases comprising 4 with intrauterine infection, 5 with adnexitis and 4 with pelveoperito-nitis were intravenously treated with AZT at a dose of 1g twice daily.
The overall clinical results were excellent in 3 cases and good in 10 cases.
3. No side effects were observed in any of the cases treated with AZT.
